Signos CEO Sharam Fouladgar-Mercer appeared on CNBC’s Fast Money to discuss the company’s recently FDA-cleared continuous glucose monitoring system for weight management. The interview, presented by Annika Kim Constantino, highlighted how the wearable device provides real-time insights into users’ metabolism, helping them understand how diet, exercise, and lifestyle choices affect weight.
During the segment, Fouladgar-Mercer described the system as “almost like a Bloomberg terminal for your metabolism,” emphasizing how it gives users timely, actionable guidance – such as whether to take a short walk after a meal – through an AI-driven platform. He also explained that the device, which uses a small biosensor attached to the body, can support both weight loss and maintenance, and is designed to complement other treatments like GLP-1 therapies.
Priced at $129 per month and eligible for FSA/HSA, the Signos system integrates with popular wearable devices, including smart watches and rings, providing users with continuous metabolic feedback outside of a doctor’s office. The interview showcased the company’s mission to make metabolic monitoring accessible and actionable for everyday weight management.